Reactions of eosinophilic granulocytes in the sputum and peripheral blood of children suffering from bronchial asthma with signs of eosinophilic and non-eosinophilic inflammation of the bronchi

  • O. K. Koloskova Bukovinian State Medical University
  • T. M. Bilous Bukovinian State Medical University
  • M. V. Dikal Bukovinian State Medical University
  • U. V. Lomakina Bukovinian State Medical University
  • T. G. Kopchuk Bukovinian State Medical University
  • T. O. Lobanova Bukovinian State Medical University
Keywords: NBT-test, airway inflammation, eosinophil cationic protein, asthma


The aim of research was to improve the management of bronchial asthma in children by examining the peculiarities and diagnostic value of reaction markers of eosinophil granulocytes in the sputum and peripheral blood of patients with signs of eosinophil and non-eosinophil phenotypes of this disease. A cohort of 118 school-age children suffering from BA was examined during a period free from attacks. Group I (the main group ) included 61 schoolchildren with signs of eosinophil phenotype (EP) of asthma detected by the character of bronchial inflammation with eosinophil granulocytes present in the sputum at a level of >3%, group II (the comparison group) included 57 patients with a lower number of eosinophils in the sputum (non-eosinophil phenotype (NP) of BA). The average index of the relative content of eosinophils in the peripheral blood among the representatives of group I was 5.82 ± 0.63%, and in children with the signs of NPBA – 6.02 ± 0.74% (P > 0.05), and average indices in the groups of absolute eosinophil number in the blood were 0.37 ± 0.04 and 0.41 ± 0.05 respectively (P > 0.05). The negative reserve of NBT eosinophils in the sputum as a test to verify EPBA showed the following diagnostic values: specificity – 83.3%, predicted value of a positive result – 95.6%. IL-5 content in the blood serum of children with EPBA was 5.99 ± 1.74 ng/ml, in patients of group ІІ – only 1.99 ± 0.49 ng/ml (P < 0.05). Eosinophil cationic protein (ЕСР) in the sputum of patients of group I reached 2.72 ± 0.35 ng/ml, and in the comparison group – only 1.74 ± 0.34 ng/ml (P < 0.05), when the content of ECP in sputum was >1.0 ng/ml the risk of EPBA showed a statistically significant increase: OR = 4.13, RR = 2.02, and AR – 0.34. The efficacy of the standardized basic anti-inflammatory therapy in patients of clinical group I was higher as compared to the children with the signs of NPBA, which was illustrated by the reduced risk of inadequate control of the disease: the index of absolute risk decrease was 31.7%, relative risk – 57.1% with necessary minimal number of patients – 1.75. 


Beasley, R., Roche, W. R., Roberts, J. A., & Holgate, S. T. (1989). Cellular events in the bronchi in mild asthma and after bronchial provocation. American Review of Respiratory Disease, 139(3), 806–817. >>
Boulet, L-P., Boulet, V., & Milot, J. (2002). Нow should we quantify asthma control?: A proposal. Chest, 122(6), 2217–2223. >>
Broide, D. H. (2008). Immunologic and inflammatory mechanisms that drive asthma progression to remodeling. Journal of. Allergy and Clinical Immunology, 121, 560–570. >> /
Chatila, T. A., Li, N., Garcia-Lioret, M., Kim, H. J., & Nel, A. E. (2008).
T-cell effector pathway in allergic diseases: Transcriptional mechanisms and therapeutic targets. Journal of Allergy and Clinical Immunology, 121, 812–823. >>
Gibson, P. G., Norzila, M. Z., & Fakes, K. (1999). Pattern of airway inflamma¬tion and its determinants in children with acute severe asthma. Pediatric Pulmonology, 4, 261–270.
Global Initiative for Asthma. Global Strategy for asthma management and prevention, 2016.
Haldar, P., & Pavord, I. D. (2007). Noneosinophilic asthma: A distinct clinical and pathologic phenotype. Journal of Allergy and Clinical Immunology, 119(5), 1043–1052. >>
Jacobsen, E. A., Lee, N. A., & Lee, J. J. (2014). Re-defining the unique roles for eosinophils in allergic respiratory inflammation. Clinical and Experimental Allergy, 44(9), 1119–1136. >>
Johansson, M. W., Kell, E. A., Busse, W. W., Jarjour, N. N., & Mosher, D. F. (2008). Up-regulation and activation of eosinophil integrins in blood and airway after segmental lung antigen challenge. The Journal of Immunology, 180, 7622–7635. >>
Kamath, A. V., Pavord, I. D., Ruparelia, P. R., & Chilvers, E. R. (2005). Is the neutrophil the key effector cell in severe asthma? Thorax, 60, 529–530.
Kato, M., Suzuki, M., Hayashi, Y., & Kimura, H. (2006). Role of eosinophils and their clinical significance in allergic inflammation. Expert Review of Clinical Immunology, 2(1), 121–133. >>
Kikuchi, S., Nagata, M., & Kikuchi, I. (2005). Association between neutrophilic and eosinophilic inflammation in patients with severe persistent asthma. International Archives of Allergy and Immunology, 137(Suppl. 1), 7–11. >>
Li, A. M., Lex, C., Zacharasiewicz, A., & Wong, E. (2003). Cough frequency in children with asthma: Correlation with lung function, exhaled nitric oxide, and sputum eosinophil count. Thorax, 58, 974–978. >>
Litvinova, L. S., Kolobovnikova, Y. V., Knutareva, Е. N., Grigoryeva, E. S., Suvorova, E. V., Novitskiy, V. V., & Riazantseva, N. V. (2006). Cytotoxic potential of eosinophilic granulocytes in patients with eosinophilic syndrome. Newsletter of Siberian Medicine, 5(3), 26–30.
Madison, J. M., & Schramm, C. M. (2000). Cationic proteins and bronchial hyperresponsiveness. American Journal of Respiratory Cell and Molecular Biology, 22(5), 513–516. >>
Mann, B. S., & Chung, K. F. (2006). Blood neutrophil activation markers in severe asthma: Lack of inhibition by prednisolone therapy. Respiratory Research, 7, 59. >>
Motojima, S., Frigas, E., Loegering, D. A., & Gleich, G. J. (1989). Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. American Review of Respiratory Disease, 139(3), 801–805. >>
Novitskiy, V. V., Riazantseva, N. V., Litvinova, L. S., Kolobovnikova, Y. V., Grigoryeva, E. S., & Suvorova, E. V. (2006). The mechanisms of disorders of eosinophils and immunocytes in the formation of gross blood eosinophilia. Newsletter of Siberian Medicine, 2, 32–34.
Pavord, I. D., 2013. Eosinophilic phenotypes of airway disease. ATS Journal, 10, 143–149. >>
Ponikau, J. U., Winter, L. A., Kephart, G. M., Squillace, D. L., & Hershcovitch, M. D. (2015). An immunologic test for chronic rhinosinusitis based on free intranasal eosinophilic major basic protein. International Forum of Allergy & Rhinology, 5(1), 28–35. >>
Shirai, T., Inui, N., & Chida, K. (2006). Correlation between peripheral blood T-cell profiles and airway inflammation in atopic asthma. Journal of Allergy and Clinical Immunology, 118, 622–626. >>
Wenzel, S., 2003. Mechanism of severe asthma. Clinical and Experimental Allergy, 33, 1622–1628. >>
Wilson, N. M., Bridge, P., Spanevello, A., & Silverman, M. (2000). Induced sputum in children: Feasibility, repeatability, and relation of findings to asthma severity. Thorax, 55, 768–774. >>
How to Cite
Koloskova, O., Bilous, T., Dikal, M., Lomakina, U., Kopchuk, T., & Lobanova, T. (2017). Reactions of eosinophilic granulocytes in the sputum and peripheral blood of children suffering from bronchial asthma with signs of eosinophilic and non-eosinophilic inflammation of the bronchi. Regulatory Mechanisms in Biosystems, 8(1), 15-18.

Most read articles by the same author(s)

Obs.: This plugin requires at least one statistics/report plugin to be enabled. If your statistics plugins provide more than one metric then please also select a main metric on the admin's site settings page and/or on the journal manager's settings pages.